Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2016 08:30 ET | Source: Flexion Therapeutics

Flexion Therapeutics Announces that Analysis from Phase 3 Clinical Trial of Zilretta™ for Osteoarthritis of the Knee to be presented at AAHKS

BURLINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that further analysis of Phase 3 data evaluating its investigational product,...
November 01, 2016 07:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics Reports Primary Endpoint Met in Clinical Trial Evaluating Investigational Drug Candidate Zilretta™ in Type 2 Diabetes Patients with Knee Osteoarthritis

- Results Demonstrate a Markedly Lower Rise in Blood Glucose in Patients Receiving a Zilretta Injection Compared to Patients Receiving an Immediate- Release Triamcinolone Acetonide Injection...
October 28, 2016 08:30 ET | Source: Flexion Therapeutics

Flexion Therapeutics to Report Third-Quarter 2016 Financial Results on November 7, 2016

BURLINGTON, Mass., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its third-quarter 2016...
September 29, 2016 08:30 ET | Source: Flexion Therapeutics

Flexion Therapeutics Announces Appointment of John Magee as Vice President of Sales

BURLINGTON, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has appointed John Magee as Vice President of Sales, the latest of several...
September 14, 2016 08:30 ET | Source: Flexion Therapeutics

Flexion Therapeutics Announces Appointment of Mark Stejbach to its Board of Directors

BURLINGTON, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today the appointment of Mark Stejbach, Senior Vice President and Chief Commercial Officer...
September 12, 2016 08:30 ET | Source: Flexion Therapeutics

Flexion Therapeutics Announces Two Key Corporate Appointments

BURLINGTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has made two key appointments to its leadership team: Carolyn Beaty Scimemi,...
August 31, 2016 08:30 ET | Source: Flexion Therapeutics

Flexion Therapeutics to Present at 2016 Wells Fargo Healthcare Conference

BURLINGTON, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will provide a...
August 03, 2016 16:01 ET | Source: Flexion Therapeutics

Flexion Therapeutics Reports Second-Quarter 2016 Financial Results

Positive data from completed pivotal Phase 2b and Phase 3 registration trials for Zilretta™, Flexion’s non-opioid lead drug candidate (also known as FX006), presented at Osteoarthritis Research...
July 25, 2016 08:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics to Report Second-Quarter 2016 Financial Results on August 3, 2016

BURLINGTON, Mass., July 25, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its second-quarter 2016...
July 06, 2016 08:00 ET | Source: Flexion Therapeutics

Flexion Therapeutics Adds Three New Executives in Key Roles to Support the Planned Commercial Launch of Zilretta™

BURLINGTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that three new executives have joined the company in key marketing, medical affairs...